<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
    xmlns:content="http://purl.org/rss/1.0/modules/content/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:atom="http://www.w3.org/2005/Atom"
    xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
    xmlns:media="http://search.yahoo.com/mrss/">
<channel>
    
        <item>
            <title>Oxford vaccine trial shows strong results in older adults - The Daily Guardian</title>
            <link>https://latest.thedailyguardian.com/others/oxford-vaccine-trial-shows-strong-results-in-older-adults/</link>
            <guid>https://latest.thedailyguardian.com/others/oxford-vaccine-trial-shows-strong-results-in-older-adults/</guid>
            <pubDate>November 20, 2020, 7:24 am</pubDate>
            <description><![CDATA[NEW DELHI: In a major development, UK’s Covid-19 vaccine has shown similar strong immune response in healthy older adults -aged 56 years and above- to those seen in people between 18 to 55 years, according to findings from a phase-2 trial. The Oxford Covid-19 vaccine has collaborated with Indian drug maker—Serum Institute of India (SII) [&hellip;]
]]></description>
            <content:encoded><![CDATA[
<p>NEW DELHI: In a major development, UK’s Covid-19 vaccine has shown similar strong immune response in healthy older adults -aged 56 years and above- to those seen in people between 18 to 55 years, according to findings from a phase-2 trial. The Oxford Covid-19 vaccine has collaborated with Indian drug maker—Serum Institute of India (SII) for which phase 2 clinical trials are being conducted in India also. The findings of the study have been published in the leading medical journal ‘Lancet’.</p>
]]></content:encoded>
            <media:content url="https://latest.thedailyguardian.com/wp-content/uploads/2020/07/vaccine-1.png" type="image/png" width="1200" height="675"/>
            <dc:creator>Our Bureau</dc:creator>
            <category></category>
        </item>
</channel>
</rss>